Navigation Links
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
Date:3/7/2013

ability to ensure an adequate and continued supply of OFIRMEV to meet market demand; Cadence's ability to successfully enforce its marketing exclusivities and intellectual property rights, and to defend the patents covering OFIRMEV, including in current patent litigation with the parties that have submitted abbreviated new drug applications ("ANDAs") for generic versions of OFIRMEV; the potential that Cadence may be required to continue patent litigation for substantial lengths of time or file additional lawsuits to defend its patent rights from challenges by companies that have submitted ANDAs for generic versions of OFIRMEV, and the substantial costs associated with such lawsuits; the potential introduction of generic competition to OFIRMEV in the event Cadence is unsuccessful in current or future patent litigation; Cadence's dependence on its licensors for the maintenance and enforcement of its intellectual property rights; the potential product liability exposure associated with pharmaceutical products such as OFIRMEV and other products Cadence may in-license or acquire; Cadence's ability to fully comply with numerous federal, state and local laws and regulatory requirements that apply to its commercial activities; public concern regarding the safety of drug products such as OFIRMEV, which could result in the implementation by regulatory agencies of new requirements to include unfavorable information in the labeling for OFIRMEV; the risk that Cadence may not be able to raise sufficient capital when needed, or at all; and other risks detailed under "Risk Factors" and elsewhere in Cadence's periodic reports and other filings made with the Securities and Exchange Commission from time to time. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995, and Cadence undertakes no obligation to revise or update this pr
'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
2. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
3. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013
4. Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
5. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
6. Cadence Pharmaceuticals to Host Analyst and Investor Day
7. Cadence to Open Finished Medical Device Facility
8. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
9. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
10. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
11. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015  ViewRay™, a privately held medical device company, announced ... agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) ... treatment of cancer in Japan . ... first and only MRI-guided radiation therapy system that images ...
(Date:1/22/2015)... Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ), ... innovative proprietary products to treat voiding dysfunctions, today reported ... 31, 2014.  Global revenue for the Company,s ... million, a new quarterly revenue record, as compared to ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the ... therapies for cardiovascular disease and overall health is pleased to ... 2014 and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... March 16, 2011 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore Ltd. ... largest retail drugstore chain in China based on the number ... for the fourth quarter and fiscal year ended December 31, ... quarter ended December 31, 2010: Same store sales ...
... is conducting a voluntary nationwide recall of the following products:Con c entate dSodi u m ... l e Do s e V i al N DC# ... o di u mCh l or i d eInjection ,USP, 2 ... ka g e N DC# 0 5 1 7 -2 ...
Cached Medicine Technology:China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2010 Financial Results 2China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2010 Financial Results 3China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2010 Financial Results 4China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2010 Financial Results 5China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2010 Financial Results 6China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2010 Financial Results 7China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2010 Financial Results 8China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2010 Financial Results 9China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2010 Financial Results 10China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2010 Financial Results 11China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2010 Financial Results 12American Regent Initiates Voluntary Nationwide Recall of Concentrated Sodium Chloride Injection, USP, 23.4% 30 mL Single Dose Vials and 100 mL Pharmacy Bulk Packs 2American Regent Initiates Voluntary Nationwide Recall of Concentrated Sodium Chloride Injection, USP, 23.4% 30 mL Single Dose Vials and 100 mL Pharmacy Bulk Packs 3American Regent Initiates Voluntary Nationwide Recall of Concentrated Sodium Chloride Injection, USP, 23.4% 30 mL Single Dose Vials and 100 mL Pharmacy Bulk Packs 4American Regent Initiates Voluntary Nationwide Recall of Concentrated Sodium Chloride Injection, USP, 23.4% 30 mL Single Dose Vials and 100 mL Pharmacy Bulk Packs 5
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 As interest in ... health care gains momentum worldwide, Rev. Eric J. Hall ... Chaplaincy Network (HCCN), will be the keynote speaker on ... in Israel’s public health system. , The conference, “Hope and ...
(Date:1/22/2015)... a new blog post explaining the importance of keeping a first ... an auto insurance policy . , Clients who driver safer ... vehicle insurance policies. The safety a vehicle offers from its driver ... this, drivers should always carry a first aid kit in their ...
(Date:12/26/2014)... 26, 2014 The US represents the largest ... In 2013, GlobalData’s forecast estimates that sales of branded therapies ... due to the high incidence of the disease, high drug ... Japan, and China. Increased sales of CRC therapies over the ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... After superman having enthralled the audience world over it is the ... of nutrients are ruling the roost these days.// ,Tesco has ... ,The catch is that they are a little expensive if you ... ,Likewise there are many other foods which are touted as good ...
... are wrong. In fact, they are at increased risk of ... from Britain's Mental Health Foundation (MHF) studied over 1,000 people ... feelings of stress, anxiety and depression, reported the online edition ... know that they are putting themselves at increased risk of ...
... a common assumption that the elderly patients who are ... intervention programs, till such time they come out of ... being excluded from such intervention modules. Infact, Researchers have ... in elderly patients with diabetes and the extent to ...
... of insulin that could revolutionize diabetic treatment has been rejected ... drug can be inhaled and provides an ideal alternative to ... ,Patients with both Type 1 and Type 2 diabetes ... associated with this form of insulin has been projected to ...
... patient died after a serious burn injury that occurred instantly ... treated with a flammable gel for a skin problem. Apparently, ... the fire escape. ,All other patients have expressed ... adherence to correct procedures, and are treating this incident as ...
... announced that on Tuesday tests carried out by Sudanese authorities ... flu, but the announcement did not state if the virus ... chickens were found at two farms in Sudan's Khartoum and ... Salih said, that the samples would be sent abroad for ...
Cached Medicine News:Health News:Superfoods make super healthy humans?? 2Health News:High Cost Forces NHS To Reject Inhaled Insulin 2
Less traumatic jaws offer a firm grasp while a self-retaining spring maintains hold on the needle. Use for grasping, applying endoloops, and driving needles during extracorporeal suturing....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: